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Abstract
Background: Acute kidney injury (AKI) is a recognized complication of pediatric severe malaria, but its long-term
consequences are unknown.
Methods: Ugandan children with cerebral malaria (CM, n = 260) and severe malaria anemia (SMA, n = 219) or
community children (CC, n = 173) between 1.5 and 12 years of age were enrolled in a prospective cohort study.
Kidney Disease: Improving Global Outcomes (KDIGO) criteria were used to retrospectively define AKI and chronic
kidney disease (CKD). Cognitive testing was conducted using the Mullen Scales of Early Learning in children < 5
and Kaufman Assessment Battery for Children (K-ABC) second edition in children ≥ 5 years of age.
Results: The prevalence of AKI was 35.1%, ranging from 25.1% in SMA to 43.5% in CM. In-hospital mortality was 11.9%
in AKI compared to 4.2% in children without AKI (p = 0.001), and post-discharge mortality was 4.7% in AKI compared to
1.3% in children without AKI (p = 0.030) corresponding to an all-cause adjusted hazard ratio of 2.30 (95% CI 1.21, 4.35).
AKI was a risk factor for short- and long-term neurocognitive impairment. At 1 week post-discharge, the frequency of
neurocognitive impairment was 37.3% in AKI compared to 13.5% in children without AKI (adjusted odds ratio (aOR) 2.
31 [95% CI 1.32, 4.04]); at 1-year follow-up, it was 13.3% in AKI compared to 3.4% in children without AKI (aOR 2.48
[95% CI 1.01, 6.10]), and at 2-year follow-up, it was 13.0% in AKI compared to 3.4% in children without AKI (aOR 3.03
[95% CI 1.22, 7.58]). AKI was a risk factor for CKD at 1-year follow-up: 7.6% of children with severe malaria-associated AKI
had CKD at follow-up compared to 2.8% of children without AKI (p = 0.038) corresponding to an OR of 2.81 (95% CI 1.
02, 7.73). The presenting etiology of AKI was consistent with prerenal azotemia, and lactate dehydrogenase as a marker
of intravascular hemolysis was an independent risk factor for AKI in CM and SMA (p < 0.0001). In CM, AKI was
associated with the presence and severity of retinopathy (p < 0.05) and increased cerebrospinal fluid albumin
suggestive of blood-brain barrier disruption.
Conclusions: AKI is a risk factor for long-term neurocognitive impairment and CKD in pediatric severe malaria.
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Background
Infection with Plasmodium falciparum is a significant
cause of global morbidity and mortality: an estimated
219 million cases of malaria were reported in 2017 with
92% of estimated cases occurring in sub-Saharan Africa
[1]. Severe malaria is also a leading cause of acquired
neurodisability in African children [2]. Clinical risk fac-
tors described to date for neurocognitive impairment in
severe malaria are acute neurologic manifestations, e.g.,
duration of coma and number of seizures [2–6].
Although children with severe malaria may present
with signs suggesting a focal insult, multi-organ dysfunc-
tion is common [7–9]. Acute kidney injury (AKI) is a
common complication of pediatric severe malaria [9, 10]
associated with mortality [9–13] and neurologic deficits
in survivors [10]. In a meta-analysis of predictors of
mortality in African children with severe malaria, AKI
was the strongest predictor of death with an odds ratio
of 5.96 (95% confidence interval (CI) 2.93 to 12.11) [14].
AKI is an established clinical risk factor for chronic kid-
ney disease (CKD) in adults [15], but information on
long-term renal recovery after AKI in pediatric popula-
tions is lacking. In particular, there are no data on
whether AKI in severe malaria is a risk factor for CKD.
In this prospective cohort study, we evaluated the
prevalence of AKI in pediatric severe malaria at admis-
sion and investigated the relationship between AKI and
clinical and renal recovery, and also with long-term neu-
rocognitive functioning.
Methods
Study participants
The study was performed at Mulago National Referral
Hospital in Uganda from 2008 to 2015, enrolling
children 18 months to 12 years of age as described [4]
(Additional file 1). All children with P. falciparum on
blood smear who met the inclusion criteria for cerebral
malaria (CM) and severe malarial anemia (SMA) were
enrolled. Children with CM had a coma with no other
identifiable cause ruling out meningitis, a prolonged
postictal state, or hypoglycemia-associated coma re-
versed by a glucose infusion. Children with SMA had
hemoglobin level ≤ 5 g/dL. Children with CM and severe
anemia were classified as CM. Age-matched community
children (CC) were recruited from the nuclear family,
extended family, or household area of children with se-
vere malaria (CM or SMA). Exclusion criteria included
prior coma, head trauma, hospitalization for malnutri-
tion, cerebral palsy, or known chronic illness requiring
medical care or causing developmental delay.
Children were managed according to the Uganda Clin-
ical Guidelines at the time of the study, including intra-
venous infusion of 10 mg/kg quinine hydrochloride in
5–10 mL/kg of 5% glucose over a 4-h period for the
treatment of severe malaria, repeated every 8 h until the
child could take oral medication (quinine or artemether-
lumefantrine). Towards the end of the study, the
treatment shifted towards the use of parenteral
artemisinin-based therapies for the treatment of severe
malaria following the 2011 World Health Organization
recommendation of injectable artesunate as the first-line
treatment for severe malaria. Hypoglycemia was treated
with a 1–2-mL/kg 25% dextrose bolus administered
intravenously. Fluid resuscitation was managed conser-
vatively according to local guidelines at the time of the
study: a fluid bolus of 20 mL/kg of sodium chloride 0.9%
intravenously over 1 h was given only for the treatment
of shock (systolic blood pressure < 50mmHg or absent
peripheral pulse) with delayed capillary refill (> 2 s).
Children without shock but with evidence of dehydra-
tion received maintenance intravenous fluids. Furosem-
ide was administered to children with clinical evidence
of congestive heart failure or lack of urine output over
one or more 8-h shifts, after ruling out dehydration
and shock, at a dose of 1 mg/kg up to a maximum of
4 mg/kg daily. Dialysis was not available on site at the
time the study was conducted.
All children underwent a medical history and physical
examination on enrollment. As a measure of disease
severity, we evaluated the number of severe malaria cri-
teria present (Additional file 1: Table S1, Methods). Emo-
tional stimulation was assessed using age-appropriate
versions of the Home Observation for the Measurement
of the Environment (HOME) [4].
Laboratory assessment
Peripheral blood smears were used to quantify parasite
density using Giemsa staining with standard protocols.
EDTA anticoagulated plasma was collected at admission
and stored at − 80 °C until testing. Plasma PfHRP2 levels
were measured to assess parasite biomass (Cellabs,
Australia) [16]. Creatinine was tested on cryopreserved
enrollment samples using a Beckman Coulter AU680
using the modified Jaffe method (Indiana University,
Pathology Laboratory). Samples were sent in batches to
the clinical laboratory for creatinine testing between
2012 and 2014, and 1-year follow-up samples were
tested in 2016.
Assessment of kidney function
Acute kidney injury (AKI) was defined retrospectively
using Kidney Disease: Improving Global Outcomes
(KDIGO) guidelines [17] based on a single admission
creatinine level, with baseline creatinine estimated using
CC as described in Additional file 1. AKI was defined as
a 1.5-fold increase in creatinine over baseline and was
staged: stage 1, 1.5–1.9× increase in creatinine over
baseline; stage 2, 2.0–2.9× increase over baseline; and
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stage 3, ≥ 3.0× increase over baseline [17]. Chronic kidney
disease (CKD) was defined as an eGFR< 90mL/min/
1.73 m2 using the Bedside Schwartz equation and catego-
rized using KDIGO guidelines [18]. The AKI classification
was repeated using an epidemiologic method to estimate
baseline creatinine [19] (Additional file 1: Table S2). A
comparative analysis is presented in Additional file 1.
Neurocognitive assessment
Children were tested at enrollment (CC) or a week after
discharge (CM, SMA) and at 1- and 2-year follow-up.
Cognition in children less than 5 years of age was
assessed by the Mullen Scales of Early Learning. Scores
from fine motor, visual reception, receptive language,
and expressive language scales were summed to give the
early learning composite score, a measure of the overall
cognitive ability. Cognitive ability in children 5 years of
age and older was assessed by the Kaufman Assessment
Battery for Children second edition (KABC-II). The
composite score for the mental processing index was
used to assess the child’s cognitive ability. Both tests
have been validated previously in Ugandan children
[2, 4]. Neurocognitive impairment was defined as the
presence of a gross deficit on neurologic exam or an
age-adjusted cognitive z score more than two stand-
ard deviations below the mean.
Statistical analyses
Age-adjusted z scores for cognition were created using
the community children [2, 3]. Unadjusted comparisons
for continuous and categorical measures used the Wil-
coxon rank-sum test or Kruskal-Wallis test and Pear-
son’s χ2 or Fisher’s exact test, respectively. Logistic
regression was used to estimate factors’ association with
AKI and to test the association between AKI, retinop-
athy, and neurocognitive outcomes. Ordinal logistic
regression was used to assess the relationship between
AKI and the ordinal categories of retinopathy. Cox pro-
portional hazards regression was used to evaluate the
association between AKI and death. Logistic regression
was used to evaluate the association between AKI and
cerebrospinal fluid albumin. Adjusters were included in
multivariable analyses if they had p < 0.10 in a bivariate
analysis or an a priori hypothesized relationship with the
outcome. Holm’s correction was used to adjust for mul-
tiple comparisons. Analyses were done using Stata v14.0
(StataCorp. 2015).
Role of the funding source
The funders had no role in the study design, analysis, or
decision to publish.
Results
In total, 652 children with enrollment creatinine values
were included in the study (Fig. 1). The demographic
characteristics of the population are presented in Table 1.
The prevalence of AKI was 35.1% overall: 43.5% of
children with CM and 25.1% of children with SMA.
Children with CM had a more severe AKI than children
with SMA (CM: 23.5% stage 1 (n = 61), 12.7% stage 2 (n
= 33), 7.3% stage 3 (n = 19); SMA: 16.0% stage 1 (n = 35),
7.3% stage 2 (n = 16), 1.8% stage 3 (n = 4), p < 0.0001).
Children with CM had a 2.37-fold (95% CI 1.38, 4.08)
increase in the odds of severe AKI (AKI stage 2 or 3)
compared to children with SMA (p = 0.010). The preva-
lence of AKI was similar in children treated with quin-
ine, 34.7% (n = 133), vs. those treated with parenteral
artemisinin derivatives, 36.0% (n = 55), p = 0.78.
Fluid management, kidney function, and hydration status
The distribution of supportive care and fluid manage-
ment by severe malaria group and AKI status is shown
in Table 2. Blood products were commonly administered
with 368 children (76.8%) receiving a transfusion during
hospitalization. Details on the type of transfusion were
available for 107 children, with 104 (96.3%) receiving
packed red blood cells. Seventy-three (15.2%) children
enrolled in the study received intravenous fluids (includ-
ing 0.9% saline, Ringer’s lactate, or albumin) in addition
to parenteral antimalarial therapy. No children fulfilled
the criteria for an intravenous fluid bolus. Children with
SMA and AKI were more likely to receive a dextrose
bolus, and children with CM and AKI were more likely
to receive intravenous fluids, a blood transfusion, and
furosemide (adjusted p < 0.05, following Holm’s correc-
tion for multiple comparisons; Table 2).
Mortality
Overall, the mortality was 9.2% with 44 deaths during
the 2-year study period: 33 (75%) occurring during
hospitalization and 11 (25%) occurring during follow-up.
With the exception of 1 child with SMA who died of
hypoglycemia, all in-hospital study deaths occurred in
children with CM and were related to respiratory failure.
Four (12.1%) children had clinical signs of cerebral
edema identified as a contributing cause of death. Chil-
dren who died were more likely to have received intra-
venous fluids during admission (33.3%, n = 11/33)
compared to survivors (13.9%, n = 62/446) (p = 0.003)
with the effect stronger in children without AKI (OR
(95% CI), 3.69 (1.07, 12.68), p = 0.038) compared to chil-
dren with AKI (OR (95% CI), 2.12 (0.78, 5.77), p = 0.14).
Most follow-up deaths (7 of 11) occurred in the first
6 months of follow-up, and all follow-up deaths
occurred in children who had severe anemia at the time
of study enrollment. Details on the cause of death in
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follow-up were limited as several deaths occurred out of
the hospital, but a history of fever, anemia, and malaria
was common.
Association between AKI and clinical recovery
Consistent with previous reports, AKI was associated
with increased mortality (Fig. 2). In-hospital mortality
was 11.9% (n = 20/168) for children with AKI compared
to 4.2% (n = 13/311) in children without AKI (p = 0.001),
and post-discharge mortality was 4.7% (n = 7/148) in
children with AKI compared to 1.3% (n = 4/298) in chil-
dren without AKI (p = 0.030) (Additional file 1: Tables
S10-S11). Overall, 60.6% of in-hospital deaths and 63.6%
of post-discharge deaths occurred in children with AKI.
In total, 326 (68.1%) children were treated with intraven-
ous quinine, and 153 (31.9%) were treated with parenteral
artemisinin derivatives. In children receiving quinine, 14
(12.4%) children with AKI died compared to 13 (6.1%)
children without AKI (p = 0.050). In children receiving
artemisinin derivatives, 6 (10.9%) of those with AKI died
compared to 0 (0.0%) children without AKI (p = 0.001).
From admission to 2-year follow-up, AKI had an adjusted
hazards ratio (aHR) for the death of 2.30 (95% CI 1.21,
4.35) following adjustment for age, sex, hemoglobin,
disease severity, and parenteral antimalarial treatment
(quinine vs. artemisinin derivative) (p = 0.0109).
Among the CM survivors, AKI was associated with pro-
longed fever clearance time (p < 0.0001), coma duration
(p < 0.0001), and length of hospitalization (p = 0.0005)
(Additional file 1: Table S10-S11). Among the SMA survi-
vors, recovery times were not associated with AKI status.
Association between severe malaria, AKI, and chronic
kidney disease 1 year later
In children with a history of severe malaria, AKI was a
risk factor for CKD with 9 (7.6%) children with AKI on
admission having CKD at 1 year follow-up (7.1% in
SMA, 7.8% in CM) compared to 7 (2.8%) children with-
out AKI (odds ratio for CKD 2.81 [95% CI 1.02, 7.73]).
In children with a history of CM, severe AKI was associ-
ated with a 4.08-fold (95% CI 1.03, 16.09) increase in the
odds of CKD. Thirteen children with CKD (81.3%) were
GFR category 2 (eGFR, 60–89mL/min/1.73 m2) and 3
(18.8%) category 3 (eGFR, 30–59). The prevalence of
CKD in children treated with quinine was 3.1% (n = 8/
257) compared to 7.3% (n = 8/109) in children treated
with artemisinin derivatives (p = 0.071). When stratifying
by AKI status at enrollment, the prevalence of CKD
without AKI was 1.7% (n = 3/173) in children treated
with quinine vs. 5.4% (n = 4/74) in children treated with
artemisinin derivatives (p = 0.202), and in children with
AKI, the prevalence of CKD was 6.0% (n = 5/84) in
children receiving quinine vs. 11.4% (n = 4/35) in chil-
dren treated with artemisinin derivatives (p = 0.446).
Children were screened for active illness prior to the
blood draw, so the eGFR was unlikely to represent a
repeat episode of AKI (detailed in Additional file 1:
Methods).
Association between AKI and neurocognitive outcomes
Neurologic deficits were common in CM survivors
1 week post-discharge (36.4%, n = 82) and consisted of
speech difficulties (31.7%, n = 26), visual impairment
(19.5%, n = 16), motor deficits (54.9%, n = 45), movement
disorders (4.9%, n = 4), ataxia (47.6%, n = 39), and hypor-
eflexia or Babinski sign (32.9%, n = 27). Deficits persisted
in only 3.1% of children (n = 7) at 2-year follow-up and
were related to speech (71.4%) and movement disorders
or motor deficits (85.7%). Overall, 53.3% (n = 48/90) of
children with AKI had a neurologic deficit 1 week
post-discharge compared to 25.2% (n = 34/135) of
children without AKI (p < 0.0001). When stratifying by
anti-malarial treatment, the association between AKI
and neurologic deficit at discharge remained significant
BASELINE
1-YEAR
FOLLOW-UP
ASSESSED FOR ACUTE
KIDNEY INJURY
ASSESSED FOR  CHRONIC
KIDNEY DISEASE
718 children enrolled
66 missing baseline
creatinine
652 children included
in the analysis
219 severe malaria
anemia
260 cerebral
malaria
173 community
children
154 community
children
174 severe malaria
anemia
194 cerebral
malaria
33 children died
22 no creatinine
6 lost to follow-up
5 withdrawn
7 children died
27 no creatinine
9 lost to follow-up
2 withdrawn
0 children died
10 no creatinine
3 lost to follow-up
6 withdrawn
Fig. 1 Flow chart of the study population. Children with a creatinine on study enrollment were included in the study and had their kidney
function re-assessed at 1-year follow-up
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with OR (95% CI) of 3.31 (1.67, 6.56) in children treated
with quinine (p = 0.0006) and 5.20 (1.62, 16.74) in chil-
dren treated with artemisinin derivatives (p = 0.006). The
association between AKI and neurologic deficits per-
sisted at 2-year follow-up: 6.7% (n = 6/90) of children
with a history of AKI had a neurologic deficit com-
pared to 0.7% (n = 1/136) in children without a his-
tory of AKI (p = 0.017).
As children surviving severe malaria are at risk of
long-term neurocognitive impairment [5], we tested the
association between AKI and neurocognition. AKI was
associated with neurocognitive impairment 1 week post-
discharge, with aOR (95% CI) of 2.31 (1.32, 4.04), and
the effect persisted over time with aORs (95% CI) of
2.48 (1.01, 6.10) and 3.03 (1.22, 7.58) at 1- and 2-year
follow-up, respectively (Fig. 3; Additional file 1: Tables
S12-S13). The associations remained significant at 2-year
follow-up after correction for multiple comparisons.
Models were adjusted for demographic factors known to
be associated with child development (age, sex, parental
Table 1 Demographic and laboratory characteristics of study children
Characteristic CC (n = 173) SMA (n = 219) CM (n = 260) p value
Demographics
Age, median (IQR), years 3.6 (2.6, 4.6) 2.9 (2.1, 4.5) 3.5 (2.5, 4.9) 0.0002
Female sex, (%) no. 94 (54.3) 86 (39.3) 107 (41.2) 0.006
Weight-for-age z score, median (IQR) − 1.0 (− 1.5, − 0.3) − 1.5 (− 2.2, − 0.7) − 1.2 (− 1.9, − 0.5) 0.0001
Height-for-age z score, median (IQR) − 1.1 (− 1.7, − 0.4) − 1.0 (− 1.9, − 0.3) − 0.6 (− 1.9, − 0.5) 0.002
Socioeconomic status score, median (IQR)1 9 (8, 12) 9 (7, 11) 9 (8, 11) 0.355
Home environment z score, median (IQR)1 0.12 (− 0.71, 0.85) − 0.05 (− 0.71, 0.67) − 0.02 (− 0.71, 0.71) 0.523
Maternal education level, no. (%)1
Primary 6 or lower 47 (27.2) 88 (38.6) 80 (36.7) 0.348
Primary 7 42 (24.3) 47 (20.6) 45 (20.6)
Secondary or higher 74 (42.8) 80 (35.1) 83 (38.1)
Not known 10 (5.8) 13 (5.7) 10 (4.6)
Paternal education level, no. (%)1
Primary 6 or lower 24 (13.9) 50 (22.9) 38 (16.7) 0.076
Primary 7 33 (19.1) 31 (14.2) 40 (17.5)
Secondary or higher 90 (52.0) 98 (45.0) 98 (43.0)
Not known 26 (15.0) 39 (17.9) 52 (22.8)
Child any education, no. (%)1 72 (41.9) 56 (26.3) 85 (38.1) 0.008
Laboratory characteristics2 SMA vs. CM
Hemoglobin, g/dL 11.8 (11.0, 12.6) 3.9 (3.2, 4.5) 6.8 (5.1, 8.7) < 0.0001
Glucose, mmol/L – 6.4 (4.7, 8.2) 6.6 (4.9, 8.9) 0.162
Lactate, mmol/L – 4.8 (3.0, 8.0) 3.8 (2.2, 6.7) 0.002
WBC, × 103/μL 8.6 (7.2, 10.6) 11.5 (8.2, 16.2) 9.4 (7.2, 13.9) 0.0001
Platelet, ×103/μL 383 (289, 449) 149 (91, 225) 60 (34, 111) < 0.0001
Total bilirubin, mg/dL 0.2 (0.1, 0.3) 1.3 (0.7, 2.1) 1.6 (0.9. 2.7) 0.004
Lactate dehydrogenase (LDH), U/L 162 (232, 311) 762 (621, 990) 829 (630, 1116) 0.069
Plasma albumin, g/dL 3.7 (3.4, 3.9) 2.6 (2.3, 3.0) 2.6 (2.4, 2.9) 0.898
Sodium, mmol/L 137 (135, 138) 134 (132, 136) 132 (128, 136) < 0.0001
Peripheral parasite density, parasites/uL 0 (0, 0) 34,970 (10,085, 134,925) 48,420 (10,830, 282,400) 0.0286
Plasma PfHRP2, ng/mL 5 (5, 118) 944 (367, 2790) 2828 (1024, 5546) < 0.0001
Creatinine, mg/dL 0.30 (0.24, 0.35) 0.35 (0.28, 0.46) 0.42 (0.31, 0.55) < 0.0001
BUN, mg/dL 7 (5, 9) 13 (9, 20) 17 (12, 25) < 0.0001
Continuous measures presented as median (interquartile range) unless otherwise indicated. Continuous measures compared using the Kruskal-Wallis test. Count
measures compared using Pearson’s chi-square or Fisher’s exact, as appropriate
1Assessed on survivors (n = 218 in SMA, n = 228 in CM)
2Data on laboratory characteristics presented for all children, as available, but analyzed using Wilcoxon rank-sum test comparing the differences between SMA
and CM
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education, school attendance, socioeconomic status, en-
richment in the home environment, and height- and
weight-for-age z scores), a composite measure of disease
severity, complications associated with impaired cogni-
tion (number of seizures, coma), and parenteral antimal-
arial treatment (quinine vs. artemisinin derivative).
Etiology and pathophysiology of AKI in severe malaria
The majority of children with severe malaria had a BUN
to creatinine ratio consistent with prerenal azotemia
(CM, 96.5%; SMA, 89.6%). There was no association
between hydration status (capillary refill time, sunken
eyes, decreased skin turgidity, cool peripheries, systolic
blood pressure, dry mucous membranes) or comorbidities
associated with volume depletion (i.e., gastroenteritis) and
prerenal azotemia in children with CM or SMA (p > 0.05
for all). Among children with severe malaria, prerenal
azotemia was associated with an increased heart rate
(p = 0.004) and lower weight-for-age (p = 0.01) and
weight-for-height z scores (p = 0.004). Children with
severe malaria and prerenal azotemia had a higher
parasite density (p = 0.001) and parasite biomass
(plasma HRP-2, p = 0.002) than children without pre-
renal azotemia. In a multivariable model, a one-unit
Fig. 2 Mortality associated with acute kidney injury and across stages of AKI over 2-year follow-up. Kaplan-Meier plots showing 2-year survival in
children with severe malaria based on the presence of KDIGO-defined acute kidney injury (AKI) status at admission (a) or the severity of AKI based
on KDIGO-defined AKI stage (b). The break in the horizontal axis separates the first 7 days of follow-up (where the majority of in-hospital deaths
occur) from the period of outpatient follow-up. Testing used the log-rank Mantel-Cox test in (a) and log-rank test for trend across stages
of AKI (b)
Fig. 3 Association between acute kidney injury and neurocognitive recovery in children following severe malaria. Bar graphs showing the
frequency of neurocognitive impairment in children with cerebral malaria (a) or severe malarial anemia (b). Neurocognitive impairment was
defined as a gross deficit on the neurologic exam or an age-adjusted z score more than two standard deviations below the mean. Data analyzed
using Pearson’s chi-square, *p < 0.01, **p < 0.01, ***p < 0.0001. c. Odds ratio of neurocognitive impairment (95% CI) associated with acute kidney
injury from logistic regression models, 1 week post-discharge and 1- and 2-year follow-up. Multivariable-adjusted models included child age, sex,
height- and weight-for-age z score, parental education, child schooling, an assessment of enrichment in the home environment, socioeconomic
status, disease severity on presentation, the presence of coma, and number of seizures during hospitalization and parenteral antimalarial
treatment (quinine vs. artemisinin derivative). *p < 0.05, **p < 0.01, ***p < 0.0001 following adjustment for multiple comparisons
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increase in the natural log of plasma HRP2 was asso-
ciated with an aOR of prerenal injury of 1.28 (1.15,
1.66) following adjustment for age, sex, heart rate,
and weight-for-age and weight-for-height z score.
In bivariate analysis, AKI was associated with disease
severity, hemoglobinuria, low glucose concentrations,
high concentrations of lactate, total bilirubin, lactate
dehydrogenase (LDH), and parasite biomass (plasma
HRP-2) (Table 3, Additional file 1: Table S3-S7). How-
ever, in multivariable models, LDH was the only meas-
ure independently associated with AKI in both CM and
SMA following adjustment for multiple comparisons
(Additional file 1: Table S4-S5). A one-unit increase in
the natural log of LDH was associated with adjusted
odds ratios (aOR) of AKI of 5.10 (95% CI 2.22, 11.69)
and 8.62 (3.02, 24.60) in CM and SMA, respectively.
History of nephrotoxic medication use was not associ-
ated with AKI at admission.
Children in coma underwent an eye exam using indir-
ect ophthalmoscopy. AKI was associated with an in-
crease in the frequency of peripheral and macular
whitening, the frequency and severity of retinal hemor-
rhages, and the number of retinopathy categories
positive (Additional file 1: Table S8-S9). Following ad-
justment for retinopathy risk factors [20] and multiple
comparisons, AKI was associated with peripheral and
macular whitening and the number of retinopathy cat-
egories positive with aOR 2.60 (95% CI 1.20, 5.21), 2.82
(1.49, 5.30), and 2.30 (1.36, 3.89), respectively. AKI was
not significantly associated with vessel color changes or
papilloedema (p > 0.05). To explore whether AKI was as-
sociated with changes in blood-brain barrier integrity, we
evaluated albumin concentrations in the CSF of children
with CM who had a lumbar puncture to rule out meningi-
tis. A one-unit increase in the natural log of cerebrospinal
fluid albumin was associated with an aOR of 2.78 (95% CI
1.56, 4.93; p < 0.001) for having AKI on admission.
Discussion
Acute kidney injury (AKI) is a well-established complica-
tion of severe malaria in adults [13], but only recently it
has been recognized as a common complication in chil-
dren with severe malaria [10]. Prior studies established
an association between AKI and mortality in severe mal-
aria [9–13]. The present study confirms a strong associ-
ation of AKI with mortality in children, with over 60% of
deaths occurring in children with AKI. This study also
demonstrated an association between AKI and persistent
neurologic deficits in children with CM, and long-term
neurocognitive impairment in children with CM and
SMA. Further, this study suggests that AKI in children
with severe malaria is associated with CKD. Together,
the results show that AKI is a common complication of
severe malaria in African children associated with major
adverse long-term health outcomes.
The etiology of AKI in pediatric severe malaria is
generally attributed to reduced renal perfusion, and this
study supports prerenal azotemia as a presenting eti-
ology of AKI. Prerenal azotemia was not associated with
clinical measures of dehydration in this cohort apart
from an elevated heart rate. However, children with pre-
renal azotemia had higher parasite density and biomass,
consistent with impaired tissue perfusion related to
microvascular sequestration of parasitized erythrocytes.
Fluid management was conservative with the majority of
children receiving intravenous quinine with blood trans-
fusion and maintenance fluids in the first 24 h of
hospitalization (Table 2). The relationship between AKI
and mortality in the present study does not appear to be
related to aggressive fluid replacement therapy. Ques-
tions remain regarding the most appropriate and safe
approach to fluid resuscitation in the context of severe
malaria complicated by severe anemia and impaired tis-
sue perfusion [21, 22], particularly in settings of severe
resource constraints where nursing care is limited and
mechanical ventilation is unavailable.
AKI was associated with the presence, severity, and
extent of retinopathy and the presence of coma and
blood-brain barrier impairment in this study. We
hypothesize microvascular changes in the retina and
brain are associated with generalized systemic micro-
vascular changes in severe malaria. Parasite biomass was
related to prerenal injury, consistent with studies in
adults with severe malaria-associated AKI [23]. Ultra-
structural examination of kidney tissue of adults with
fatal malaria reveals parasite sequestration in glomerular
and tubulointerstitial vessels and monocyte accumula-
tion in glomerular capillaries [24]. In children, renal
sequestration is less frequent, but still occurs, and may
potentially contribute to AKI [8].
Histologic findings of malaria pigment in distal convo-
luted tubules [8] are consistent with the reports of intra-
vascular hemolysis and increased cell-free hemoglobin
and heme in malaria-associated AKI [25, 26]. In the
present study, LDH was strongly associated with AKI,
supporting the hypothesis that hemolysis contributes to
oxidative stress and pigment nephropathy. This is fur-
ther supported by increased bilirubin, another marker of
hemolysis, and increased frequency of hemoglobinuria
in AKI. A recent clinical trial showed a renoprotective
effect of acetaminophen in adults with severe malaria
and intravascular hemolysis [27]. Retrospective data
from pediatric cardiac surgery suggest early postopera-
tive acetaminophen reduces hemoglobin-mediated oxi-
dative stress and AKI [28]. The present study supports a
role for hemolysis and increased cell-free hemoglobin in
pediatric AKI and highlights the need for renoprotective
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adjunctive therapies to reduce the incidence and severity
of AKI in pediatric malaria.
In this study, AKI was associated with CKD at 1-year
follow-up, consistent with a growing body of evidence
that AKI is a risk factor for short-term [29] and
long-term CKD and end-stage kidney disease in children
[30]. Although AKI can result in persistent and progres-
sive renal dysfunction, even complete recovery is associ-
ated with subsequent risk of developing CKD [15]. For
example, between 8 and 61% of children who recovered
baseline renal function following hemolytic uremic syn-
drome developed renal complications within 5 to
10 years [31]. The present study is the first to report an
association between AKI and CKD in the context of se-
vere malaria. We are currently planning to follow up the
study participants to re-evaluate kidney function 5 to
12 years after severe malaria.
Distant organ injury in AKI is well-described, and
neurologic complications including central nervous
system dysfunction, decreased mental status, and sei-
zures are associated with AKI [32]. The presence of
mild-to-moderate CKD is associated with deficits in aca-
demic achievement, executive function, and visual and
verbal memory [33], but to our knowledge, this is the
first report of an association between AKI and neuro-
cognitive impairment. Well-recognized risk factors for
neurocognitive impairment in severe malaria relate to
neurological complications on admission and inflamma-
tory and neuroactive metabolites in cerebrospinal fluid
[2–5, 34–36]. Increased cerebrospinal fluid albumin in
children with CM and AKI suggests blood-brain barrier
impairment. Many processes known to be important in
cognitive impairment, including endothelial dysfunction,
oxidative stress, and inflammation, also relate to AKI
[32]. The relationship of AKI to neurocognitive impair-
ment could reflect the contribution of these processes to
both clinical entities, or reflect an independent role for
AKI in neurocognitive impairment, through mechanisms
still to be defined.
In the present study, the frequency of CKD was higher
in children treated with artemisinin derivatives, though
with the small number of children with CKD, these
differences did not approach statistical significance. This
study highlights the need for additional studies to assess
CKD in children treated with artemisinin derivatives.
The association between AKI and mortality and neuro-
cognitive impairment was seen in children treated with
either drug, so this association occurs independently of
severe malaria treatment.
Strengths of the study include its sample size, rigorous
clinical definitions, prospective design, and careful
neurocognitive follow-up. Including the community con-
trols to estimate premorbid creatinine likely increased
our ability to detect AKI. Further, our findings are con-
sistent irrespective of the method used to define premor-
bid creatinine, suggesting an epidemiologic approach is
valid when premorbid creatinine measurements or com-
munity controls are unavailable. The study is the first to
Table 2 Supportive care and treatment in children with severe malaria according to AKI status
Severe malarial anemia (n = 219) Cerebral malaria (n = 260)
No AKI (n = 164) AKI (n = 55) p value No AKI (n = 147) AKI (n = 113) p value
Supportive care
Oxygen 22 (6.7) 7 (12.7) 0.160 71 (48.3) 76 (67.3) 0.002
Antipyretics 161 (98.2) 53 (96.4) 0.437 138 (93.9) 104 (92.0) 0.562
Medications
Quinine 127 (77.4) 44 (80.0) 0.691 131 (89.1) 99 (87.6) 0.707
Artesunate/artemether 55 (33.5) 16 (29.1) 0.619 43 (29.3) 39 (34.5) 0.420
Anticonvulsants 1 (0.6) 2 (3.6) 0.156 109 (74.2) 96 (85.0) 0.034
Furosemide 32 (19.5) 11 (20.0) 0.937 9 (6.1) 26 (23.0) < 0.0001
Bolus dextrose 28 (17.1) 28 (50.9) < 0.0001 132 (89.8) 91 (80.5) 0.034
Intravenous fluids 12 (7.3) 5 (9.1) 0.671 24 (16.3) 32 (28.3) 0.020
0.9% saline 10 (6.1) 4 (7.3) 0.754 18 (12.2) 24 (21.2) 0.051
Ringer’s lactate 0 (0.0) 0 (0.0) – 2 (1.4) 4 (3.5) 0.246
10% dextrose 0 (0.0) 0 (0.0) – 4 (2.7) 2 (1.8) 0.700
Bicarbonate 0 (0.0) 0 (0.0) – 0 (0.0) 1 (0.9) 0.435
Darrow’s 0 (0.0) 1 (1.8) 0.251 1 (0.7) 0 (0.0) 1.000
Albumin 2 (1.2) 0 (0.0) 1.000 2 (1.4) 4 (3.5) 0.408
Blood transfusion 164 (100.0) 55 (100.0) – 68 (46.3) 81 (71.7) < 0.0001
Data presented as n (%) and compared using Pearson’s chi-square or Fisher’s exact, as appropriate
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Table 3 Measures associated with acute kidney injury
Severe malarial anemia (n = 219) Cerebral malaria (n = 260)
No AKI (n = 164) AKI (n = 55) p value No AKI (n = 147) AKI (n = 113) p value
Demographics
Age, years 2.8 (2.1, 4.2) 3.2 (2.0, 4.9) 0.375 3.6 (2.7, 5.4) 3.2 (2.2, 4.5) 0.014
Sex, F % 65 (39.6) 21 (38.2) 0.849 59 (40.1) 48 (42.3) 0.705
Weight-for-age z score − 1.5 (− 2.2, − 0.7) − 1.8 (− 2.4, − 0.6) 0.439 − 1.0 (− 1.8, − 0.4) − 1.4 (− 1.9, − 0.8) 0.044
Height-for-age z score − 1.0 (− 1.8, − 0.3) − 1.4 (− 2.6, − 0.5) 0.119 − 0.7 (− 1.3, 0.3) − 1.0 (− 1.9, − 0.1) 0.024
Weight-for-height z score − 0.9 (− 1.8, − 0.1) − 0.9 (− 1.6, − 0.1) 0.697 − 1.0 (− 1.8, − 0.1) − 1.0 (− 1.7, − 0.3) 0.914
HIV-infected, n (%) 5 (3.1) 1 (1.9) 1.000 1 (0.7) 4 (4.0) 0.165
Sickle cell disease
(HbSS), n (%)
17 (10.4) 4 (7.3) 0.605 1 (0.7) 0 (0.0) 0.380
Admission characteristics
Symptoms
History of fever, days 4 (3, 5) 3 (2, 5) 0.078 3 (2, 4) 3 (2, 4) 0.537
Tea-colored urine, n (%) 23 (14.0) 15 (27.3) 0.025 18 (12.2) 27 (23.9) 0.014
Diarrhea, n (%) 10 (6.1) 6 (10.9) 0.235 6 (4.1) 6 (5.3) 0.640
Vomiting, n (%) 74 (45.1) 38 (69.1) 0.002 60 (40.8) 38 (33.6) 0.236
Clinical signs
Temperature, °C 37.7 (37.0, 38.5) 37.7 (36.7, 38.5) 0.976 38.0 (36.9, 38.5) 37.6 (37.0, 38.5) 0.161
Pulse, beats/min 150 (137, 162) 154 (138, 168) 0.158 148 (128, 165) 150 (135, 168) 0.278
Respiratory rate,
breaths/min
44 (36, 55) 40 (35, 52) 0.358 44 (34, 54) 44 (36, 56) 0.357
Systolic blood pressure,
mmHg
90 (82, 100) 90 (85, 100) 0.708 96 (90, 105) 96 (85, 104) 0.409
Blantyre coma score 5 (5, 5) 5 (5, 5) – 2 (1, 2) 2 (1, 2) 0.684
Glasgow coma score 15 (15, 15) 15 (15, 15) – 7 (6, 8) 7 (6, 8) 0.760
Severe dehydration, n
(%)1
4 (2.4) 3 (5.5) 0.371 4 (2.7) 3 (2.7) 1.000
Urine hemoglobin
positive, n (%)
10 (7.7) 8 (19.5) 0.032 14 (10.8) 28 (33.7) < 0.0001
Hemoglobinuria, n (%) 16 (9.8) 13 (23.6) 0.009 10 (6.9) 21 (18.6) 0.004
Laboratory tests
Hemoglobin, g/dL 4.0 (3.1, 4.6) 3.8 (3.4, 4.3) 0.942 7.2 (5.7, 9.0) 6.0 (4.8, 7.9) 0.0002
Glucose, mmol/L 6.8 (5.0, 8.2) 5.3 (4.1, 7.2) 0.002 6.9 (5.4, 9.6) 6.1 (4.6, 4.6) 0.032
Lactate, mmol/L 4.6 (2.8, 7.7) 5.5 (3.6, 9.5) 0.052 3.3 (2.0, 6.1) 4.3 (2.8, 8.0) 0.003
WBC, × 103/μL 11.2 (8.2, 15.7) 12.3 (9.2, 22.3) 0.117 8.3 (6.3, 12.3) 10.8 (7.9, 17.4) 0.0008
Platelet, × 103/μL 155 (95, 242) 133 (82, 197) 0.179 62 (35, 112) 51 (33, 109) 0.225
Total bilirubin, mg/dL 1.1 (0.6, 1.9) 1.5 (0.9, 2.9) 0.007 1.4 (0.8, 2.0) 2.0 (1.0, 3.6) 0.0001
Lactate dehydrogenase
(LDH), U/L
728 (591, 879) 990 (754, 1510) < 0.00001 712 (537, 906) 1090 (797, 1513) < 0.00001
Plasma albumin, g/dL 2.6 (2.4, 3.0) 2.6 (2.3, 3.2) 0.737 2.6 (2.3, 3.0) 2.7 (2.4, 2.9) 0.467
Sodium, mmol/L 134 (132, 136) 135 (132, 137) 0.383 132 (128, 135) 133 (129, 136) 0.180
Peripheral parasite density,
parasites/uL
34,680 (10,435, 133,980) 40,070 (6085, 138,470) 0.868 50,820 (13,910, 287,835) 42,140 (8000, 249,560) 0.338
Plasma PfHRP2, ng/mL 886 (326, 2344) 1415 (382, 3453) 0.151 2244 (655, 3965) 4394 (2208, 7469) < 0.00001
Creatinine, mg/dL 0.31 (0.26, 0.38) 0.53 (0.48, 0.67) < 0.00001 0.33 (0.29, 0.39) 0.58 (0.49, 0.78) < 0.00001
BUN, mg/dL 11 (8, 16) 22 (15, 30) < 0.00001 13 (10, 17) 26 (18, 41) < 0.00001
Composite disease severity score
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assess the relationship between AKI and CKD in mal-
aria, and the largest pediatric study to date to assess
post-AKI CKD.
Among the study limitations are the retrospective
definition of AKI, using a single measurement of creatin-
ine on admission and estimating pre-illness creatinine
from community control data. The study definition
likely underestimates AKI [37]. Further investigation, in-
cluding detailed urinalysis and renal biopsy findings, is
also needed to understand the pathophysiology of AKI
in children with severe malaria. Additional studies are
needed to evaluate AKI in low-resource settings to
understand whether the findings in this paper are
generalizable to all critically ill hospitalized children or
specific to severe malaria-associated AKI.
Conclusions
In summary, the present study supports a growing body
of evidence that AKI is a risk factor for long-term mor-
bidity and mortality in malaria, providing new evidence
that AKI is a risk factor for sustained neurocognitive im-
pairment in survivors. Further, this study suggests that
children with severe malaria-associated AKI may be at
risk of developing CKD. This has far-reaching implica-
tions for the burden of non-communicable disease in
Uganda, where the prevalence of CKD is estimated at
18.1% [38] and renal replacement therapy is not available
in most areas. To make progress towards the Inter-
national Society of Nephrology initiative to eliminate
preventable deaths from AKI worldwide by 2025 (0by25)
[39], a concerted effort to improve diagnosis, and
management, of AKI in resource-constrained malaria-
endemic settings is urgently needed.
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Severe malarial anemia (n = 219) Cerebral malaria (n = 260)
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Number of severity
criteria2
3 (2, 3) 3 (2, 4) 0.0029 4 (3, 4) 4 (3, 5) 0.0004
Nephrotoxic medication history3
NSAIDs4 12 (7.3) 3 (5.5) 0.224 15 (10.2) 15 (13.3) 0.442
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Continuous measures presented as median (interquartile range) unless otherwise indicated. Continuous measures compared using the Wilcoxon rank-sum test.
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5NSAID or gentamicin
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